Amsterdam UMC
Amsterdam UMC is recorded as a service provider in 10 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 10 of 10 trials · Latest update first
A Phase 2, Multi-cohort Study Applying Innovative MRD Techniques for Transplant Eligible Participants with Previously Untreated Multiple Myeloma - TAURUS
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
- Not reported
ANTICIPATE: Prevention of ANThracycline-Induced Cardiac dysfunction by dexrazoxane In PATients with diffusE large B-cell lymphoma: a phase III national multicenter prospective randomized open-label trial
Sponsor Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)
- Start (EU)
- Latest update
- Estimated end
- Not reported
HOVON 156 AML: A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy.
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
HOVON 151 DLBCL: A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diffuse large B-cell lymphoma.
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
- Not reported
HOVON 169 CAD: Phase II trial of Zanubrutinib in primary Cold Agglutinin Disease. CaZa study
Sponsor Haemato Oncology Foundation For Adults Netherlands
- Start (EU)
- Latest update
- Estimated end
- Not reported
HOVON 174 MM: FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – the FABULOUS study
Sponsor Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)
- Start (EU)
- Latest update
- Estimated end
- Not reported
HOVON 165 CLL: A prospective randomized phase I/II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or Small Lymphocytic Lymphoma. AETHER study (ABT199 + Epcoritamab THErapy for Relapsed/refractory CLL/SLL)
Sponsor Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)
- Start (EU)
- Latest update
- Estimated end
- Not reported
HOVON 164 HL: Tislelizumab plus Gemcitabine and Cisplatin for Relapsed or Refractory Hodgkin Lymphoma followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission (TIGERR-HL). An open label phase II trial.
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
- Not reported
HOVON 171 AML: A single arm phase II trial to assess cobicistat boosted venetoclax in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (AML) who are not considered candidates for intensive treatment regimens
Sponsor Haemato Oncology Foundation For Adults Netherlands
- Start (EU)
- Latest update
- Estimated end
- Not reported
HOVON 152 DLBCL. A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly diagnosed high grade B cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements
Sponsor Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Amsterdam UMC?
The 2026-10-09 snapshot links Amsterdam UMC to 10 distinct CTIS trials. Recorded services include Laboratory services, Imaging review, Biobanking, Molecular MRD, ImmunoMRD, Molecular Diagnostics, Biobanking. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Amsterdam UMC?
The most frequently recorded therapeutic areas are Haematological Malignancies, Cardiology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Amsterdam UMC conducted?
The linked trials record locations in 14 countries, including Netherlands, Belgium, Germany, Denmark, Austria. These are trial locations, not confirmed office locations or countries where Amsterdam UMC delivered services.
What can this page tell me about Amsterdam UMC's trial experience?
Browse 10 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Amsterdam UMC. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Amsterdam UMC